Letrozole for Fertility

Letrozole is an aromatase inhibitor. Its FDA label covers adjuvant and extended adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, and first and second-line treatment of advanced breast cancer. Nothing on that label mentions ovulation, conception or infertility. Every prescription written for fertility in the United States is off-label, and the 2023 international guideline says it plainly: the use of ovulation induction agents, including letrozole, metformin and clomiphene citrate, is off-label in many countries. Off-label is the ordinary status of this whole drug class rather than a red flag, but your prescriber should say it out loud before you start.

The mechanism is a deliberate, temporary hormone crash. Short-term administration during the early follicular phase suppresses ovarian and peripheral estrogen synthesis by approximately 97 to 99 percent, producing a transient hypo-estrogenic milieu. Your brain reads that dip as a shortage and responds: the decline in circulating estradiol removes the normal negative feedback on the hypothalamic-pituitary axis, leading to increased pulsatile gonadotropin-releasing hormone output and a subsequent rise in pituitary follicle-stimulating hormone and luteinizing hormone secretion. More FSH recruits a follicle. That is the whole trick, and it lasts about a week.

The trial that moved practice is PPCOS II, published in 2014. It randomized 750 women with PCOS to letrozole or clomiphene for up to five cycles, with live birth as the primary outcome rather than a surrogate. Women who received letrozole had more cumulative live births than those who received clomiphene, 103 of 374 (27.5%) versus 72 of 376 (19.1%), P=0.007, rate ratio 1.44, 95% confidence interval 1.10 to 1.87. Read that as roughly one extra live birth for every twelve treated, which is a meaningful edge and not a transformation.

Ovulation moved the same way. The cumulative ovulation rate was higher with letrozole than with clomiphene, 834 of 1352 treatment cycles (61.7%) versus 688 of 1425 cycles (48.3%), P<0.001. A Cochrane review pooling 41 randomized trials in 6,522 women found the same direction with stronger certainty: live birth rates were higher with letrozole compared to SERMs followed by timed intercourse, odds ratio 1.72, 95% CI 1.40 to 2.11, high-certainty evidence, and a separate meta-analysis of 26 trials put the probability of ovulation higher with letrozole, risk ratio 1.148, 95% CI 1.077 to 1.223.

Notice what did not move. There were no significant between-group differences in pregnancy loss, 49 of 154 pregnancies in the letrozole group (31.8%) and 30 of 103 in the clomiphene group (29.1%). Close to a third of pregnancies in both arms ended in loss. Letrozole improves your odds of ovulating and conceiving in a given cycle. It does nothing measurable to protect a pregnancy once it has started, and any service implying otherwise is selling you something the trial never showed.

Clomiphene is a selective estrogen receptor modulator, so it occupies estrogen receptors well beyond the pituitary, and it lingers. Its own label reports that zuclomiphene has a longer half-life than enclomiphene, with detectable levels persisting for longer than a month, while the prolonged anti-estrogenic activity of clomiphene may adversely affect estrogen-sensitive tissues such as the endometrium and cervical mucus. Letrozole never touches the receptor and clears in days, so by the time your lining and mucus need estrogen, estrogen is back. The biology behind that contrast is sound.

The size of the effect is far less settled than the story implies. A meta-analysis of 33 randomized trials found that in 15 trials comparing clomiphene with letrozole, endometrial thickness was lower in the clomiphene group, weighted mean difference -1.39 mm, 95% CI -2.27 to -0.51. Real, but modest, and that pooled figure carried an I-squared of 100%, meaning the trials essentially disagree with each other. In the same analysis ovulation rates after clomiphene and letrozole were comparable, RR 0.97, 95% CI 0.90 to 1.04. Treat the lining as one plausible mechanism, not the proven reason letrozole wins.

Letrozole fixes exactly one problem: you are not releasing an egg reliably. The guideline recommendation is narrow and the qualifier at the end is the part that gets dropped in marketing copy. Letrozole should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS, with no other infertility factors. If ovulation is not your bottleneck, a drug that induces ovulation changes nothing about your odds, and it costs you cycles finding that out.

The trial's entry criteria draw the boundary better than any checklist. PPCOS II enrolled participants who were 18 to 40 years of age, had at least one patent fallopian tube and a normal uterine cavity, and had a male partner with a sperm concentration of at least 14 million per milliliter. Tubal blockage, significant male factor and diminished ovarian reserve were screened out before randomization, so the trial says nothing about them.

In those situations letrozole is not a slower route to the same destination. It is the wrong lever, and a tubal patency test and a semen analysis belong before cycle three rather than after cycle six.

Against clomiphene the guideline is direct: letrozole should be used rather than clomiphene citrate in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation, clinical pregnancy and live birth rates. On twins the two drugs sit closer than reputation suggests. Cochrane reported multiple pregnancy rates of 2.2% with SERMs versus 1.6% with letrozole, odds ratio 0.74, 95% CI 0.42 to 1.32, high-certainty evidence, and PPCOS II found no significant difference in twin pregnancy, 3.4% and 7.4%.

Injectable gonadotropins are the sharper contrast. In the AMIGOS trial of unexplained infertility, live birth occurred in 32.2% of gonadotropin cycles, 23.3% of clomiphene cycles and 18.7% of letrozole cycles, while the multiple gestation rate was 32% with gonadotropin alone against 13% with letrozole, P=0.006. The composition differed too: all multiple gestations in the clomiphene and letrozole groups were twins, whereas gonadotropin treatment resulted in 24 twin and 10 triplet gestations. Fewer live births per cycle, and almost no triplets. One correction worth carrying with you, because it is widely garbled. AMIGOS studied unexplained infertility rather than PCOS, and letrozole did not come first there: pregnancy rates with letrozole were significantly lower than with standard therapy, though not significantly different from clomiphene alone, P=0.10. The ASRM guideline for unexplained infertility names no single winning drug and concludes that for most couples the best initial therapy is a course, typically three or four cycles, of ovarian stimulation with oral medications and intrauterine insemination, followed by in vitro fertilization for those unsuccessful.

First-line status is a PCOS finding, not a universal one.

PPCOS II used the schedule most clinics still run. Participants received letrozole 2.5 mg daily beginning on cycle day 3 for 5 days, for up to five menstrual cycles, after either a spontaneous period or a progestin-induced withdrawal bleed. Some prescribers start on day 5 instead, and the five-day block matters more than the exact start day. Once letrozole is discontinued, typically by cycle day 7 to 9, estradiol levels rise again as the dominant follicle matures, which is why timing intercourse or insemination around mid-cycle still applies.

Escalation is built into the protocol rather than improvised. The dose was increased in subsequent cycles in cases of nonresponse, defined as a midluteal progesterone level below 3 ng per milliliter, with a maximum daily letrozole dose of 7.5 mg given for 5 days. That single blood draw around day 21 is the feedback loop for the whole treatment: it tells you whether the cycle ovulated, and it is what any dose change should rest on. The guideline adds two standing instructions, that pregnancy should be excluded prior to ovulation induction therapy and that you should be monitored for adverse effects on an ongoing basis.

Trial side effects were mild and mostly unglamorous. Clomiphene was associated with a higher incidence of hot flushes, and letrozole with higher incidences of fatigue and dizziness, with rates of other adverse events similar in the two treatment groups. Ovarian hyperstimulation is the risk that generates the most worry, and Cochrane put a number on it: OHSS rates are similar with letrozole or SERMs, 0.5% in both arms, high-certainty evidence. The label also flags fatigue, dizziness and somnolence, with caution advised when operating machinery.

Then there is the line that stops most readers cold. Femara's prescribing information states that letrozole can cause fetal harm and is contraindicated for use in pregnant women. That label describes continuous daily dosing for breast cancer, where treatment could run through an entire pregnancy. Ovulation induction is five days at the start of a cycle, and letrozole's terminal elimination half-life is about 2 days, so it has cleared long before implantation. The guideline turns the same fact into a practical rule: letrozole should not be given where there is any possibility of a pre-existing pregnancy.

Search this drug and the 2005 scare surfaces within a page or two, so here it is properly. A conference abstract that year reported outcomes in 150 babies conceived on letrozole and raised the possibility of cardiac and skeletal defects. Initial case reports and a non-peer-reviewed study in the mid-2000s raised alarm about possible congenital cardiac defects in letrozole-exposed pregnancies, leading some regulators to temporarily contraindicate letrozole in women of childbearing age. It was a meeting abstract rather than a peer-reviewed paper, and it had no proper control group.

A far larger study answered it the following year across five Canadian fertility centers. Congenital malformations and chromosomal abnormalities were found in 14 of 514 newborns in the letrozole group (2.4%) and 19 of 397 in the clomiphene group (4.8%), with major malformation rates of 1.2% and 3.0%, and the rate of all congenital cardiac anomalies was significantly higher in the clomiphene group (1.8%) than the letrozole group (0.2%), P=0.02. The authors were blunt about the implication: the concern that letrozole use for ovulation induction could be teratogenic is unfounded based on our data.

Randomized evidence pointed the same way. PPCOS II found no significant differences in overall congenital anomalies, though there were four major congenital anomalies in the letrozole group versus one in the clomiphene group, P=0.65, numbers far too small to read a signal into in either direction. Two decades on, the guideline records that current evidence demonstrates no difference in fetal abnormality rates between letrozole or clomiphene citrate ovulation induction or natural conception and that there is no evidence for increased teratogenicity compared to other ovulation induction agents.

The scare still circulates. The evidence that answered it is larger, randomized and consistent.

For unexplained infertility the standard pairing is an oral agent with intrauterine insemination, which is what ASRM concludes is the best initial therapy for most couples, typically three or four cycles, followed by in vitro fertilization for those unsuccessful. For PCOS anovulation with timed intercourse, letrozole usually runs on its own. Metformin is a different instrument entirely: the same guideline that puts letrozole first also states that clomiphene citrate could be used in preference to metformin for anovulatory infertility, which places metformin third.

Two practical additions belong in the first cycle rather than later. The guideline advises that prenatal vitamins supplementation should be commenced with ovulation induction therapy aligned to routine preconception care, so folate starts before conception rather than after a positive test. And when several correctly dosed cycles fail, the next move is a different class rather than a higher dose: gonadotropins alone could be considered rather than clomiphene citrate in therapy naive women with PCOS with anovulatory infertility, with ovarian surgery and IVF behind that.

The tablet is not where the money goes. CMS publishes what pharmacies pay to acquire generics, and the national average drug acquisition cost for letrozole 2.5 mg tablets was $0.15111 per tablet, classified as generic, in the file published on 2 September 2026. Acquisition cost is what the pharmacy pays rather than a retail or telehealth price, so what you are charged will be higher. It still frames the arithmetic: a 2.5 mg course is five tablets and even the maximum 7.5 mg course is fifteen. For comparison in the same file, clomiphene citrate 50 mg tablets carried an acquisition cost of $4.65243 each.

So judge a service on its monitoring rather than its prescribing speed. This page is information rather than medical advice, and the prescribing decision belongs to a licensed clinician who knows your history. Ask whether a midluteal progesterone is ordered every cycle and who reviews the result, because that number is the only evidence a cycle worked. Ask whether tubal patency and a semen analysis are required before a third cycle, since letrozole addresses neither. Ask what happens at cycle four if nothing has changed, and whether the answer is a referral or another refill. A service with one move is a poor fit for a condition with several.